Capital Group Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$796K Buy
13,127
+932
+8% +$54.3K 0.14% 113
2025
Q4
$658K Sell
12,195
-1,092
-8% -$52.5K 0.11% 124
2025
Q3
$599K Hold
13,287
0.1% 128
2025
Q2
$615K Hold
13,287
0.11% 127
2025
Q1
$810K Hold
13,287
0.17% 112
2024
Q4
$752K Hold
13,287
0.14% 120
2024
Q3
$687K Buy
+13,287
New +$623K 0.14% 121
2024
Q2
Sell
-59,638
Closed -$3.23M 146
2024
Q1
$3.23M Sell
59,638
-90,061
-60% -$4.59M 0.58% 48
2023
Q4
$7.68M Sell
149,699
-155,746
-51% -$8.18M 0.81% 34
2023
Q3
$17.7M Sell
305,445
-23,161
-7% -$1.42M 1.15% 25
2023
Q2
$21M Buy
328,606
+59,542
+22% +$3.99M 1.05% 31
2023
Q1
$18.6M Sell
269,064
-127,909
-32% -$9.02M 1% 34
2022
Q4
$28.6M Buy
+396,973
New +$29.9M 1.1% 31

Other funds holding BMY

Capital Group Investment Management's BMY Position: Q1 2026 in Review

Capital Group Investment Management increased its Bristol-Myers Squibb (BMY) stake by 7.6% in Q1 2026, buying an estimated $54.3K and bringing the position to 13,127 shares worth $796K. The position accounts for 0.14% of the portfolio, ranked #113.

Capital Group Investment Management first reported a position in BMY in Q4 2022 and has held it in 13 quarters since. The position peaked at $28.6M in Q4 2022. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Capital Group Investment Management held 13,127 shares of Bristol-Myers Squibb worth $796K as of Q1 2026.
  • Capital Group Investment Management bought 932 Bristol-Myers Squibb shares in Q1 2026, an estimated $54.3K.
  • Bristol-Myers Squibb made up 0.14% of Capital Group Investment Management's portfolio in Q1 2026, its #113 holding.
  • Capital Group Investment Management first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 13 quarters since.
  • Capital Group Investment Management's Bristol-Myers Squibb position peaked at $28.6M in Q4 2022.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Capital Group Investment Management's 13F filing for Q1 2026, filed 13 May 2026.